3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia
159
Leukemia, Myeloid, Acute
134
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Lymphoma
100
Myelodysplastic Syndromes
86
Leukemia, Lymphocytic, Chronic, B-Cell
84
Burkitt Lymphoma
78
Lymphoma, Non-Hodgkin
76
Lymphoma, Follicular
72
Lymphoma, Large B-Cell, Diffuse
71
Lymphoma, Mantle-Cell
67
Lymphoma, Large-Cell, Immunoblastic
61
Lymphoma, B-Cell, Marginal Zone
58
Hodgkin Disease
54
Multiple Myeloma
44
Leukemia, Myeloid, Chronic-Phase
43
Leukemia, Myeloid, Accelerated Phase
39
Congenital Abnormalities
39
Myeloproliferative Disorders
37
Blast Crisis
34
Leukemia, Myelomonocytic, Chronic
32
Dendritic Cell Sarcoma, Interdigitating
30
Recurrence
27
Neoplasms, Plasma Cell
27
Leukemia, Biphenotypic, Acute
27
Leukemia, Myelomonocytic, Acute
26
Anemia, Refractory, with Excess of Blasts
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
24
Leukemia, Monocytic, Acute
24
Interventions
Specimen Handling
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Filgrastim
×
Other hematologic neoplasm
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled